glp 1 agonists tirzepatide Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction The GLP-1 Powerhouses: Semaglutide vs.

Age-Related Sleep Decline Melatonin production declines naturally with age older adults produce significantly less melatonin, which contributes to the lighter, more fragmented sleep patterns that characterize aging

February 2, 2026: FDA Published Second Safety Label Change of 2026 for Zepbound Eli Lillys popular weight-loss drug Zepbound had a second safety label update in January 2026

Other countries"

Brubaker says drugs need to be carefully tested in stages before they are approved for use in people

Unlocking the Potential: Amylin-Based Therapies as Novel Interventions for Addressing the Nexus of Obesity and Cardiovascular Health